case 2: diagnosing pd-l1 and egfr lung adenocarcinoma
Published 5 years ago • 70 plays • Length 6:59Download video MP4
Download video MP3
Similar videos
-
5:34
case 2: pd-l1 and egfr lung adenocarcinoma
-
5:00
case 2: testing for egfr in lung adenocarcinoma
-
2:49
case 2: stage iv pd-l1–negative, kras-mutant lung adenocarcinoma
-
5:13
case 2: frontline therapy in egfr-mutated lung cancer
-
3:09
case 2: osimertinib in egfr-mutated lung cancer
-
8:36
case study: mutation-negative patient with lung adenocarcinoma
-
3:24
nondriver lung adenocarcinoma: treatment considerations
-
7:46
egfr and pd-l1 testing in locally advanced nsclc
-
55:38
novel therapy for lung cancer: from targeted therapy to immuno-therapy and back again!
-
4:14
case based panel discussion - egfr and high pdl1 what is the role of immunotherapy in treatment?
-
5:55
a case of egfr-mutant non–small cell lung cancer
-
3:47
case overview: egfr-positive nsclc
-
59:19
precision oncology in early-stage lung cancer, with adjuvant egfr-targeted therapy leading the way
-
0:48
current role of immunotherapy in egfr-mutant lung cancer
-
1:06
dr. goldman on targeted therapy options for egfr-, alk-, and ros1-mutated nsclc
-
4:03
approaching a case of egfr non–small cell lung cancer
-
5:53
targeted therapy in non-small cell lung cancer
-
1:44
pd-l1 testing in first-line treatment of nsclc
-
5:06
case based panel discussion - egfr mutation and high pdl1 - what is the role of immunotherapy in tre